Le Lézard
Classified in: Health
Subjects: CCA, MAT

Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023


VANCOUVER, BC, Nov. 21, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2023, after market close on Wednesday, November 29, 2023.

Interested parties are invited to participate in the Company's Q4 and year-end 2023 results conference call and webcast occurring on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time. During the call, Numinus executives will review the Company's performance and recent initiatives.

A question-and-answer session will follow management's prepared remarks. At this time, the operator will provide instructions for qualified equity analysts to submit questions. Investors are invited to submit questions by email to [email protected]. A selection of questions will be answered by management on the call, and all emailed questions will be responded to by email.

To listen to the live webcast, please register at:
https://events.q4inc.com/attendee/375671679 

The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations/

To participate in the live conference call, please use the following dial-in information:

To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.

A replay of the conference call can also be accessed after 8:30 p.m. Eastern time / 5:30 p.m. Pacific time on November 29, 2023, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until December 13, 2023.

About Numinus

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model ? including psychedelic research and clinic care ? is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedInFacebookTwitter, and Instagram.

SOURCE Numinus Wellness Inc.


These press releases may also interest you

at 19:30
The "Protein Expression Market - A Global and Regional Analysis: Focus on Application, End User, Product, Expression System, and Region - Analysis and Forecast, 2023-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 19:20
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, today announced that MSCI, one of the...

at 19:15
The "Europe Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033" report has been added to  ResearchAndMarkets.com's offering. The Europe cell and gene therapy manufacturing Quality Control (QC) market is expected to reach...

at 19:00
More than ever, young girls are being exposed to adult skincare content, and it's creating societal pressure for them to adopt unnecessary anti-ageing skincare regimens before they've even grown up. To view the Multimedia New Release, Please click:...

at 18:57
CalciMedica Inc. (CalciMedica or the Company) , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases,...

at 18:52
CCA Industries, Inc. , announced today its results for the year ended November 30, 2023.  The results can be found on the chart below. Net loss was $422,866 for the year ended November 30, 2023, as compared to a net loss of $54,017 for the year...



News published on and distributed by: